Aller au contenu principal
2014 article

Short-term and Long-term Follow-up 2 - Emerging Conditions (Get Ready!) Tuesday, Oct. 28 - 10:30am-12:00pm

0Citations signalées, ce qui n’est pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Le résumé fourni par la source

Background: The New England Newborn Screening Program (NENSP) has used low citrulline (Cit) as a biomarker to screen for the proximal UCDs [ornithine transcarbamylase (OTC), carbamylphosphate synthase (CPS) deficiency, and N-acetylglutamate synthase (NAGS)] since 2004. Low plasma Cit has been reported in other metabolic disorders (pyrroline-5-carboxylate synthetase deficiency -P5CS) and Cit is used as a marker of enterocytes mass and function. We performed a retrospective analysis to evaluate the (1) determine the etiology of the false positives (FP) and (2) possibility of screening for other disorders when using low Cit as a marker in screening. Methods: The study cohort is all 1.2 M newborns screened for the proximal UCD’s in the region from Aug 2004 to Aug 2013. Cit is analyzed as part of the amino acid and acylcarnitine markers analyzed by MS/MS. A positive screen for proximal UCDs were specimens with 1) Cit 3uM to < 3.8 in conjunction with Cit/[Tyr x Met] < 0.002. Results: In 20 infants the initial specimen collected by day of life 7 screened positive for a proximal UCD. Of these infants 8 were confirmed to have a proximal UCD (5 OTC, 2 CPS, and 1 NAGS). The other 12 were concluded to be FP. Nine FP were from neonates in intensive care units (NICU) on total parenteral nutrition (TPN).The 3 neonates with FP screens who were not in the NICU showed various plasma and/or clinical anomalies on follow-up. An additional 5 infants with in-range Cit values on an initial screen and a positive screen on a subsequent screen were identified; these were all infants who had had a bowel resection and were on TPN. The newborn screening data of the only infant with P5CS deficiency in the cohort was reviewed and was noted to have a low Cit (4.2 uM), albeit above our threshold. One

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

Aucun DOI disponible pour le contrôle Crossref.

Les sujets associés

Metabolism and Genetic DisordersNeonatal Health and BiochemistryHyperglycemia and glycemic control in critically ill and hospitalized patients

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.